Tag: Selective acetylcholinesterase inhibitor

  • Donepezil

    Selective acetylcholinesterase inhibitor

    A piperidine-class selective reversible acetylcholinesterase inhibitor, FDA-approved as Aricept for Alzheimer disease, with the largest clinical evidence base of the AChE inhibitor class.

    Abstract

    Donepezil (Aricept; (R/S)-2-((1-benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-2,3-dihydro-1H-inden-1-one hydrochloride; CAS 120014-06-4; molecular formula C24H29NO3; molecular weight 379.49) is a piperidine-class selective reversible acetylcholinesterase inhibitor developed by Eisai and approved by the FDA in 1996 for mild, moderate, and severe Alzheimer disease. The compound has the highest AChE selectivity (over 1000-fold versus butyrylcholinesterase) of the marketed AChE inhibitors and a long plasma half-life (70 hours) that supports once-daily dosing. Mechanism is selective AChE inhibition without significant secondary activities at nicotinic receptors or other targets. The clinical evidence base in Alzheimer disease is extensive; multiple Phase 3 trials demonstrate small but consistent improvements in cognitive endpoint measures (ADAS-cog, MMSE) and global functional status. The compound is also approved for vascular dementia and Parkinson disease dementia in some jurisdictions. Pharmacokinetics: oral bioavailability essentially complete; metabolism is hepatic via CYP2D6 and CYP3A4 with minor active metabolites. Schedule status: prescription-only but not federally scheduled.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.